Volume : 09, Issue : 02, February – 2022

Title:

05.REVIEW ON ANGIOTENSIN RECEPTOR BLOCKERS IN BREAST CANCER

Authors :

Mrs. Rupitha N S, Mrs. Aswathy SS, Mrs. Savitha Mol G M, Dr. Silviya Navis A, Dr. Prasobh G R, Ms. Surabhi G S, Ms. Jiji Mohan M U

Abstract :

Drug discovery is a time-consuming, costly and high-risk process. It usually takes 10-15 years to develop a new drug. Drug repurposing is an alternative approach of drug discovery. Drug Repurposing (DR) can be defined as a process of identification and discovery of new therapeutic uses, outside the scope of the original pharmacological indication, for already approved drugs. Cancer is a group of diseases caused by loss of cell cycle control. It is associated with uncontrolled growth of abnormal cells with the ability to invade local tissues and metastasis which are proliferating individually throughout the body. These abnormal cells are termed cancer cells, malignant cells, or tumor cells.

Cite This Article:

Please cite this article in press Rupitha N S et al, Review On Angiotensin Receptor Blockers In Breast Cancer., Indo Am. J. P. Sci, 2022; 09(02). .

Number of Downloads : 10

References:

1. Shreshtha M, Sarangadhara B, Uma S and Sunita S. Epidemiology of Breast Cancer In Indian Women. Asia-Pacific Journal of Clinical Oncology. 2017;8(4):1-7.
2. Oleg V, Denis M and Samarin. Pathogenesis of Cancer: Cancer Reparative. Journal of Cancer Therapy. 2015; 6: 399-412.
3. Hanqing X, Haozhe X, and Yadong. Review of Drug Repositioning Approaches And Resources. International Journal of Biological Sciences. 2018;14(10): 1232-1244.
4. Deotarse P P, Jain A S and Baile M B. Drug Repositioning: A Review. International Journal of Pharma Research Review. 2015; 4:51-58.
5. Ashburn T and Thor K B. Drug Repositioning: Identifying and Developing New Uses For Existing Drugs. Nat Rev Drug Discovery Journal. 2015; 3: 673-83.
6. Chia-Ing Jan and Ming-Hsuiand Tsai. Fenofibrate Suppresses Oral Tumorigenesis Via Reprogramming Metabolic Processes: Potential Drug Repurposing For Oral Cancer. International Journal of Biological Sciences. 2016; 12(7): 786-798.
7. Xin Lian, Gang Wang, Honglan Zhou, Zongyu Zheng And Yaowen, Lu Cai, Anticancer Properties of Fenofibrate: A Repurposing Use. Journal of Cancer 2018; 9(9): 1527-1537.
8. Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati S, And Fogal V. In Vitro and In Vivo Anticancer Effects of Mevalonate Pathway Modulation On Human Cancer Cells. British Journal of Cancer. 2014; 11(1):1562–1571.
9. Fengli Zhang, Huixiao Chen, Jing D, Bin Wang, And Lixiao Yang. Anticancer Activity of Metformin, An Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/ Akt/Mammalian Target Of Rapamycin (Mtor) Signaling. International Journal of Biological Sciences. 2016; 12(7): 786-798.
10. Ali R, Mirza Z, and Ashraf. New Anticancer Agents Recent Developments In Tumor Therapy. Anticancer Research. 2017; 3(2):2999–3005.
11. Jubie S, Selvaraj A, Neethu Y, Parvesh B, Puru K, Shreyan S And Chandrasekar Mjn. Early Stage Repurposing Of Benzimidazole Scaffolds Towards Breast Cancer Through In silico Tools. Journal of Pharmaceuticals Science & Research. 2018;10(10): 2419-2423.
12. Pan P, Vidula S, Gauthier B Lydie Meheus and Vikas P Sukhatme. Repurposing Drugs In Oncology (Redo)—Diclofenac As An Anti-Cancer Agent. E Cancer. 2016;10:1-28.
13. Sonal W, Nitesh Kumar, Lalitha S, Subhankar B, Karthik G, Grandhi V, Mit J, and Mallikarjuna R. Evaluation of In Vitro And In Vivo Anticancer Potential of Two 5-Acet Amido Chalcones Against Breast Cancer. EXCLI Journal. 2017;16: 1150-1163.
14. Zia Al Sabbah, Aijaz Mansoor, and Upendra Kaul. Angiotensin Receptor Blockers – Advantages of The New Sartans. Journal of The Association of Physicians of India.6; 464-470: 2013.
15. Amit K. Khairnar, Dheeraj T. Baviskar Dinesh K. Jain. Angiotensin II Receptor Blockers: An Overview. International Journal of Pharmacy and Pharmaceutical Science.2016; 4 (3):50-56.
16. Hazel Mae A. Abraham, Michael White and William B. The Comparative Efficacy and Safety of The Angiotensin Receptor Blockers In The Management of Hypertension and Other Cardiovascular Diseases. Drug Saf Journal. 2015; 38(1): 33–54.
17. Manish Pal Singh, Devendra Pathak, Gyanendra K. Sharma, and C Sharma. Peroxisome Proliferator-Activated Receptors (PPARS): A Target With a Broad Therapeutic Potential For Human Diseases: An Overview Pharmacology Online. 2011; 2: 58-89.
18. Akhilesh K, Shraddha S, and Vijay K . Molecular Concept In Human Oral Cancer. Maxillaofacid Surgery.2015: 6(1); 9-15
19. Jesse Roman. Peroxisome Proliferator Y Activated Receptor and Lung Cancer Biology. Journal of Investigative Medicine.2011; 56(2):528–533.
20. Chia-Ing Jan, Ming-Hsuiand Tsai. Fenofibrate Suppresses Oral Tumorigenesis Via Reprogramming Metabolic Processes: Potential Drug Repurposing For Oral Cancer International Journal Of Biological Sciences 2016; 12(7): 786-798.